Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by RTOon Aug 22, 2014 8:33am

200 Views

Post# 22868153

RE:RE:Warrant Trading Float Cut In Half

Wembley, the VOUCHER to name only one. Drop that little package into this small and tight float and see what you arrive at. The home stretch towards this event will create a ton of erratic movements. What I like about this company is the transparent guidance timeline for the drugs which pinpoints timely events. The best part about the warrants is the 2016 expiry date. All of the events are scheduled by Q2-2015!!

Bullboard Posts

Changing Europe’s dependency on HREE from China